• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

    0.6702 -0.0198 (-2.87%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,084,758
    Open 0.6920
    Bid (Size) 0.6600 (1,900)
    Ask (Size) 0.7200 (200)
    Prev. Close 0.6900
    Today's Range 0.6702 - 0.7300
    52wk Range 0.4300 - 5.140
    Shares Outstanding 9,362,444
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Vistagen Therapeutics (NASDAQ:VTGN) Faces Muted Market Sentiment as Crucial PALISADE-4 Data Looms ↗
    Via Chartmill
    News headline image
    Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
    From Vistagen
    Via Business Wire

    Performance

    YTD
    -1.3%
    -1.3%
    1 Month
    +12.5%
    +12.5%
    3 Month
    +9.9%
    +9.9%
    6 Month
    -22.2%
    -22.2%
    1 Year
    -71.8%
    -71.8%

    More News

    Read More
    News headline image
    Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
    From Vistagen
    Via Business Wire
    News headline image
    Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
    From Vistagen
    Via Business Wire
    News headline image
    Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
    From Vistagen
    Via Business Wire
    News headline image
    Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
    From Vistagen
    Via Business Wire
    News headline image
    Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
    From Vistagen
    Via Business Wire
    News headline image
    Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
    From Vistagen
    Via Business Wire
    News headline image
    Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
    From Vistagen
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    VTGN DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
    From Pomerantz LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?
    Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?
    The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market
    What is the current price of Vistagen Therapeutics, Inc. - Common Stock?
    The current price of Vistagen Therapeutics, Inc. - Common Stock is 0.6702
    When was Vistagen Therapeutics, Inc. - Common Stock last traded?
    The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 06/18/26 04:00 PM ET
    What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?
    The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 6.27M
    How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?
    Vistagen Therapeutics, Inc. - Common Stock has 6M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.